Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
03/25/24, 5:33 PM
Location
new yorknew yorkIndustry
biopharma
therapeutics
biotechnology
health care
biopharma
therapeutics
pharmaceutical
biotechnology
health care
Nuvation Bio Inc. (NYSE: NUVB) and AnHeart Therapeutics Ltd. have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction. This acquisition will strengthen Nuvation Bio's position as a late-stage global oncology company with a focus on delivering novel cancer therapies.
Company Info
Location
New York, New York, United States
Company info
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.